The effect of rituximab injection combined with CHOP regimen on serum LDH and β 2-MG levels in patients with non Hodgkin′s lymphoma
10.3760/cma.j.cn431274-20230912-00252
- VernacularTitle:利妥昔单抗注射液联合CHOP方案对非霍奇金淋巴瘤患者血清LDH、β2-MG水平的影响
- Author:
Wenyue HUANG
1
;
Chen LI
;
Yuhu FENG
Author Information
1. 阜阳市人民医院血液内科，阜阳 236000
- Keywords:
Rituximab;
Antineoplastic combined chemotherapy protocols;
Lymphoma, non-Hodgkin;
Lactate dehydrogenase;
beta 2-microglobulin
- From:
Journal of Chinese Physician
2024;26(6):853-857
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of the combination of rituximab injection and cyclophosphamide+ hydroxydoxorubicin+ oncovin+ prednisone (CHOP) regimen on serum lactate dehydrogenase (LDH) and β 2-microglobulin (β 2-MG) levels in patients with non Hodgkin′s lymphoma (NHL).Methods:A total of 92 NHL patients admitted to the Hematology Department of Fuyang People′s Hospital from January 2020 to May 2023 were selected and randomly divided into an observation group ( n=46) and a control group ( n=46) using a random number table method. The control group received chemotherapy intervention with CHOP regimen; The observation group received intravenous infusion of rituximab injection 1 day before the start of CHOP chemotherapy. After 6 consecutive cycles of treatment (1 cycle for 21 days), the efficacy and adverse reactions, the levels of inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)], T lymphocytes [surface antigen differentiation cluster 4 (CD4 + ), surface antigen differentiation cluster 8 (CD8 + ), CD4/CD8, helper T cells 17 (Th17)], vascular endothelial growth factor (VEGF), LDH, and β2-MG of the two groups were compared after treatment. Results:The total remission rate of the observation group was 80.43%(37/46), which was higher than that of the control group, which was 60.87%(28/46), and the difference was statistically significant ( P<0.05). Compared with before treatment, TNF-α and IL-6 levels decreased, Th17 and CD8 + levels increased in both groups after treatment, and the difference was statistically significant (all P<0.05); After treatment, the TNF-α and IL-6 levels in the observation group were lower than those in the control group, and Th17 levels were higher than those in the control group, with statistically significant differences (all P<0.05). Compared with before treatment, the LDH, β2-MG, and VEGF levels in the two groups decreased significantly after treatment (all P<0.05); After treatment, the LDH, β2-MG, and VEGF levels in the observation group were lower than those in the control group, and the differences were statistically significant (all P<0.05). The total incidence rates of adverse reactions in the two groups were 86.96%(40/46) and 80.43%(37/46), respectively, with no statistically significant difference ( P>0.05). Conclusions:The combination of rituximab injection and CHOP regimen for NHL treatment can effectively alleviate inflammation, improve LDH, β 2-MG, VEGF levels, and enhance efficacy. The safety is similar to using CHOP regimen alone, and it is worth promoting and applying.
